As I wrote few months back, CSL facing a major competitor threat...

As I wrote few months back, CSL facing a major competitor threat from Argnex VYVGART for CIDP business.As a result the high valuation that was given in PE is coming down fast. CSL Seqirus and Vifor business will do well but in IG segment 25% is from CIDP treatment. That is about 10% overall CSL revenue. I think until this is clear and CSL has some alternative product like CSL112 in the market, it will be tough going. I will not be surprised to see 240 to 250 range.
The other alternative is to show where else can the plasma be used to fill the gap from CIDP.
Have a look at Argenx SP since release of VYVGART stage 3 trials going gang bust. I am of the opinion this is a confirmation of the nature of competition CSL has to face up to right now. This is my opinion but prepared to accept if there is any evidence to contrary.